COVID-19

COVID-19 Disruption

Read more about the impact of COVID-19 on HIV, TB and malaria services and systems for health
download in English | Français

Country-based Local Fund Agents, who monitor grant implementation and progress on behalf of the Global Fund, complete a monthly survey online to help identify potential risks and disruptions to programs. The tool is not meant to be a rigorous assessment of the country situation. The data is based on in-country stakeholder views but not on verified data. Key insights as of 1 August 2021:

Countries in lockdown: 38% of countries where the Global Fund invests are experiencing nationwide lockdowns as of 1 August, slightly up from 36% on 1 July. 25% of countries are still experiencing local restrictions that impact the programs run by the Global Fund, marking a slight decrease from 26% since 1 July.

Costed national plans: The share of countries with fully costed response plans in place for their COVID-19 response has decreased marginally. On 1 August 2021, 83% of countries had a costed response plan in place, compared to 84% on 1 July 2021, 83% on 15 November 2020, and 75% on 15 June 2020.

Disruption to health service delivery: The overall risk of disruption to malaria services has surpassed the overall risk to HIV services for the first time and is now level with the overall risk to TB services. 33% of countries are reporting no or low disruption to health service delivery for malaria, compared to 31% of countries for HIV and 25% for TB. 3% of countries are experiencing very high disruption for malaria services, compared to 1% for TB services and 0% for HIV services.

Disruption to supply of key medicines: The risk trend in the supply of key HIV medicines remains relatively high but stable as of 1 August. For the TB and malaria components, at least half of the countries where the Global Fund invests have a minimum 6 months’ supply capacity of key medicines. As of 1 August, 5% of countries were experiencing shortages for HIV medicines, 4% were experiencing shortages for TB medicines, and 1% were experiencing shortages for malaria medicines.

Lab services: As of 1 August, 41% of countries are reporting no or low HIV and/or TB lab services disruption, up from 39% on 1 July. 50% of countries are reporting moderate disruption, marking an increase from 40% on 1 May. The percentage of countries experiencing high HIV and/or TB lab services disruption has slightly increased to 4%. The share of countries reporting very high disruption has remained stable at 2% since 1 July.